Prognostic Nomogram for Triple-Negative Breast Cancer Patients with Neoadjuvant Therapy

From January 2018 to December 2024, 804 patients with triple-negative breast cancer (TNBC) who underwent neoadjuvant therapy at Henan Cancer Hospital were included. The dataset, authored by Yuehua Zhang and last updated in May 2026, contains data used to develop and validate a prognostic nomogram model for overall survival.

Use Cases

• Predicting overall survival based on clinical factors like age, tumor size, and lymph node metastasis.
• Stratifying patients into low, moderate, and high-risk groups using a point-based nomogram.
• Comparing the performance of a new prognostic model against other established factors using C-index and time-dependent ROC analysis.
• Guiding personalized treatment strategies for early-stage TNBC patients.
• Selecting comparable patient cohorts for clinical trials based on risk stratification.

Strengths

• Dataset includes 804 patient records from a single hospital.
• Model was developed using a training cohort of 603 patients and validated on an internal cohort of 201 patients.
• The prognostic model incorporates six independent factors identified in the study.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the final model data is unknown, which may limit suitability assessment.
• Data is from a single hospital in Henan, China, which may limit generalizability to other populations.

Provenance

Source

Henan Cancer Hospital

Collection Method

Clinical records of patients treated from January 2018 to December 2024.

Time Range

2018-01-01 to 2024-12-31

Freshness

Last updated 2026-05-28 04:52:37; freshness should be verified.

Geography

Henan, China